Qiagen

Company Snapshot

Founded: 1984
Entity Type: Public
Employees: 5,700
Region: U.S.
Revenue: $1,978.2 Millions
Revenue Year: 2024
Segment: Molecular diagnostics
Headquarter: PL Venlo, Netherlands
Key Geographics: Europe, Middle East and Africa, Asia-Pacific, Americas, Rest of the World
Corporate Address: Hulsterweg 82, 5912 PL Venlo Netherlands Tel. +31-77-355-6600 www.qiagen.com

Company Overview

QIAGEN was founded in 1984 and is headquartered in Venlo, Netherlands. It is a major player in molecular diagnostics, life sciences research, and applied testing. The company operates through two segments: molecular diagnostics and life sciences. The company focuses on technologies that help extract, purify, and analyze genetic materials like DNA, RNA, and proteins. QIAGEN serves various industries, including academic research, clinical diagnostics, pharmaceutical development, forensics, and agriculture, and it has a diverse range of products. Its core strengths lie in sample preparation, molecular diagnostics, and bioinformatics, supporting advances in personalized medicine, infectious disease detection, cancer genomics, and oncology diagnostics.

QIAGEN is a parent company with more than 50 consolidated subsidiaries, many of which are primarily responsible for the regional distribution of its products and services.

Qiagen In Reports

Biological and Medical Imaging Reagents: Global Markets

BCC Research Report: Dive into biological and medical imaging reagents market revenues are broken down by region and have been estimated for the five-year period from 2024 through 2029.

Biomarker Deals: Terms Value and Trends 2019-2025

BCC Research detailed report on biomarkers market report evaluates global biomarker deals between 2019 and 2025 across licensing, collaboration, M&A, and R&D partnerships.

Molecular Diagnostics: Technologies and Global Markets

According to our research analyst the molecular diagnostics market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Company's Business Segments

  • Molecular diagnostics : Molecular testing, Oncology, Infectous diseases and Immune Monitoring
  • Life Sciences : Medicine and clinical development, frorensics, exploring the building blocks of life.

Applications/End User Industries

  • Real-Time PCR Instrumentation
  • Nucleic Acid Amplification
  • Automated Systems
  • Automated Sample Preparation
  • High-Throughput Testing
  • Point-of-Care Diagnostic Systems
  • Rapid Testing
  • Clinical Settings
  • Next-Generation Sequencing (NGS)
  • Automated Liquid Handling
  • Oncology
  • Infectious Diseases
  • Molecular Pathology
  • Tissue Extraction Kits
  • Tissue-Based Diagnostics
  • Life Sciences Research
  • Genomics
  • Transcriptomics
  • Proteomics
  • High-Throughput DNA Sequencing
AI: Your Say